David Luo

1.7k total citations
16 papers, 431 citations indexed

About

David Luo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Luo has authored 16 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in David Luo's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). David Luo is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). David Luo collaborates with scholars based in United States, Italy and Australia. David Luo's co-authors include Zachary Hornby, Stephen V. Liu, Alexander Drilon, Pratik S. Multani, Manish R. Patel, Todd M. Bauer, Sai‐Hong Ignatius Ou, Alice T. Shaw, Anna F. Farago and Zongli Zheng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

David Luo

14 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Luo United States 9 252 217 185 83 46 16 431
Motoko Omura‐Minamisawa Japan 12 106 0.4× 126 0.6× 215 1.2× 102 1.2× 26 0.6× 18 418
Jürgen Wolf Germany 12 202 0.8× 275 1.3× 208 1.1× 130 1.6× 167 3.6× 25 605
Takeshi Hirao Japan 13 175 0.7× 126 0.6× 248 1.3× 68 0.8× 66 1.4× 23 534
Yuto Yasuda Japan 10 172 0.7× 221 1.0× 121 0.7× 62 0.7× 31 0.7× 35 346
Carolien Boeckx Belgium 12 109 0.4× 225 1.0× 155 0.8× 99 1.2× 40 0.9× 15 374
Giannicola DʼAddario Switzerland 6 318 1.3× 411 1.9× 124 0.7× 38 0.5× 25 0.5× 8 540
Alexander Hoellein Germany 11 49 0.2× 224 1.0× 313 1.7× 49 0.6× 53 1.2× 12 501
Changxia Shao United States 11 80 0.3× 177 0.8× 166 0.9× 48 0.6× 50 1.1× 35 398
Ludimila Cavalcante United States 12 78 0.3× 238 1.1× 148 0.8× 60 0.7× 43 0.9× 54 423
A. Tryakin Russia 10 166 0.7× 176 0.8× 115 0.6× 66 0.8× 44 1.0× 125 461

Countries citing papers authored by David Luo

Since Specialization
Citations

This map shows the geographic impact of David Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Luo more than expected).

Fields of papers citing papers by David Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Luo. The network helps show where David Luo may publish in the future.

Co-authorship network of co-authors of David Luo

This figure shows the co-authorship network connecting the top 25 collaborators of David Luo. A scholar is included among the top collaborators of David Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Luo. David Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Luo, David, et al.. (2024). Standard of practice in pharmacy informatics. Journal of Pharmacy Practice and Research. 54(2). 179–197. 1 indexed citations
2.
Luo, David, et al.. (2022). Using a Patient Identification Checklist: How to Make This a Never Safety Event in Perioperative Services. Journal of PeriAnesthesia Nursing. 37(4). e2–e2.
3.
Salerno-Gonçalves, Rosângela, et al.. (2021). B Cells Control Mucosal-Associated Invariant T Cell Responses to Salmonella enterica Serovar Typhi Infection Through the CD85j HLA-G Receptor. Frontiers in Immunology. 12. 728685–728685. 8 indexed citations
4.
Luo, David, et al.. (2020). “Double hit” anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements. American Journal of Hematology. 95(12). 1625–1627. 1 indexed citations
5.
Luo, David, et al.. (2020). Access to green space and median household income in metro Vancouver cities. 2 indexed citations
6.
7.
Sigal, Darren, Marie Tartar, Patrick J. Foley, et al.. (2017). Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. Journal of the National Comprehensive Cancer Network. 15(11). 1317–1322. 32 indexed citations
8.
Salerno-Gonçalves, Rosângela, David Luo, Stéphanie Fresnay, et al.. (2017). Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Frontiers in Immunology. 8. 398–398. 39 indexed citations
9.
Drilon, Alexander, Kamalesh K. Sankhala, Stephen V. Liu, et al.. (2017). Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Research. 77(13_Supplement). CT060–CT060. 13 indexed citations
10.
Drilon, Alexander, Filippo de Braud, Salvatore Siena, et al.. (2016). Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. Cancer Research. 76(14_Supplement). CT007–CT007. 22 indexed citations
11.
Farago, Anna F., Long P. Le, Zongli Zheng, et al.. (2015). Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 10(12). 1670–1674. 172 indexed citations
12.
Patel, Manish R., Todd M. Bauer, Stephen V. Liu, et al.. (2015). STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology. 33(15_suppl). 2596–2596. 36 indexed citations
13.
Braud, Filippo de, Monica Niger, Silvia Damian, et al.. (2015). Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology. 33(15_suppl). 2517–2517. 41 indexed citations
14.
Braud, Filippo de, Lorenzo Pilla, Monica Niger, et al.. (2014). Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology. 32(15_suppl). 2502–2502. 27 indexed citations
15.
Zhang, Cen, et al.. (2009). Essential Medical Mandarin for Health Care Providers. MedEdPORTAL.
16.
Lü, Min, Lijuan Xia, David Luo, Samuel Waxman, & Yongkui Jing. (2004). Dual effects of glutathione-S-transferase π on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene. 23(22). 3945–3952. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Motoko Omura‐Minamisawa Breakdown of academic impact, for papers by Jürgen Wolf Breakdown of academic impact, for papers by Takeshi Hirao Breakdown of academic impact, for papers by Yuto Yasuda Breakdown of academic impact, for papers by Carolien Boeckx Breakdown of academic impact, for papers by Giannicola DʼAddario Breakdown of academic impact, for papers by Alexander Hoellein Breakdown of academic impact, for papers by Changxia Shao Breakdown of academic impact, for papers by Ludimila Cavalcante Breakdown of academic impact, for papers by A. Tryakin
Rankless by CCL
2026